T cells

Sonoma Biotherapeutics Raises $265 Million in an Oversubscribed Series B Financing to Translate the Promise of Cell Therapy into Curative Medicines for Autoimmune and Other Inflammatory Diseases

Retrieved on: 
Wednesday, August 4, 2021
Research, Finance, Genetics, Clinical Trials, Professional Services, Stem Cells, Biotechnology, Pharmaceutical, Health, Science, Immunology, Branches of biology, T cells, Biology, Immune system, Regulatory T cell, Immune tolerance, Autoimmunity

Sonoma Biotherapeutics , an immune tolerance company focused on the development of regulatory T cell (Treg) therapies, has announced an oversubscribed $265 million Series B financing.

Key Points: 
  • Sonoma Biotherapeutics , an immune tolerance company focused on the development of regulatory T cell (Treg) therapies, has announced an oversubscribed $265 million Series B financing.
  • Sonoma Bio, which creates a new therapeutic paradigm, has assembled a leading world-class team who are pioneering technology to unlock this novel cell therapy approach for autoimmune and inflammatory diseases.
  • Additional Treg cell therapy discovery programs are also underway targeting other autoimmune and inflammatory diseases.
  • Sonoma Biotherapeutics is a South San Francisco and Seattle-based company leading the development of adoptive Treg cell therapies for autoimmune and inflammatory diseases.

Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

Retrieved on: 
Friday, July 30, 2021
Branches of biology, Clinical medicine, Medicine, Cancer immunotherapy, T cells, Biotechnology, Chimeric antigen receptor T cell, Immune system, Leukemia, Cell therapy, Kite Pharma, Cellectis

Celyad Oncology is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer.

Key Points: 
  • Celyad Oncology is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer.
  • The Company is developing a pipeline of allogeneic (off-the-shelf) and autologous (personalized) CAR T cell therapy candidates for the treatment of both hematological malignancies and solid tumors.
  • Celyad Oncology was founded in 2007 and is based in Mont-Saint-Guibert, Belgium and New York, NY.
  • Such risk and uncertainty include the duration and severity of the COVID-19 pandemic and government measures implemented in response thereto.

Quell Therapeutics Appoints Tracey Lodie, Ph.D., as Chief Scientific Officer

Retrieved on: 
Thursday, July 29, 2021
Branches of biology, Biology, Life sciences, Induced stem cells, Biotechnology, T cells, Stem cells, Regulatory T cell, IPSCS, Induced pluripotent stem cell

LONDON and BOSTON, July 29, 2021 /PRNewswire/ --Quell Therapeutics Ltd ("Quell"), the world leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, announces the appointment of Tracey Lodie, Ph.D., as Chief Scientific Officer.

Key Points: 
  • LONDON and BOSTON, July 29, 2021 /PRNewswire/ --Quell Therapeutics Ltd ("Quell"), the world leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, announces the appointment of Tracey Lodie, Ph.D., as Chief Scientific Officer.
  • "We are delighted to welcome Tracey to Quell.
  • She brings impressive drug discovery experience working with a wide range of cell therapy platforms, including induced pluripotent stem cells (iPSCs), Treg and T-effector cells and genetic engineering," said Iain McGill, Chief Executive Officer of Quell Therapeutics.
  • "We believe that Tracey's extensive technical and therapeutic expertise enhances our industry leading engineered Treg cell therapy development capabilities and reinforces our proven operational competency.

Quell Therapeutics Appoints Tracey Lodie, Ph.D., as Chief Scientific Officer

Retrieved on: 
Thursday, July 29, 2021
Branches of biology, Biology, Life sciences, Induced stem cells, Biotechnology, Stem cells, T cells, IPSCS, Regulatory T cell, Induced pluripotent stem cell

LONDON and BOSTON, July 29, 2021 /PRNewswire/ -- Quell Therapeutics Ltd ("Quell"), the world leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, announces the appointment of Tracey Lodie, Ph.D., as Chief Scientific Officer. Dr. Lodie brings to Quell more than 20 years of experience in the biopharmaceutical industry focused on the discovery and development of cell therapies and novel biologics in the areas of autoimmunity, transplant biology and immune-oncology.

Key Points: 
  • "We are delighted to welcome Tracey to Quell.
  • She brings impressive drug discovery experience working with a wide range of cell therapy platforms, including induced pluripotent stem cells (iPSCs), Treg and T-effector cells and genetic engineering," said Iain McGill, Chief Executive Officer of Quell Therapeutics.
  • "We believe that Tracey's extensive technical and therapeutic expertise enhances our industry leading engineered Treg cell therapy development capabilities and reinforces our proven operational competency.
  • Quell is also advancing additional programs in neuroinflammatory and autoimmune diseases.

Allogene Therapeutics to Report Second Quarter Financial Results on August 4, 2021

Retrieved on: 
Tuesday, July 27, 2021
Clinical medicine, Medicine, Health sciences, Cancer immunotherapy, T cells, Breakthrough therapy, Gene therapy, Chimeric antigen receptor T cell, Lymphoma, ALLO-715, Kite Pharma

SOUTH SAN FRANCISCO, Calif., July 27, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) therapies for cancer, today announced that it will report second quarter 2021 financial results on Wednesday, August 4, 2021, after the close of the market.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., July 27, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) therapies for cancer, today announced that it will report second quarter 2021 financial results on Wednesday, August 4, 2021, after the close of the market.
  • The announcement will be followed by a live audio webcast and conference call at 2:00 PM Pacific Time/5:00 PM Eastern Time.
  • The webcast will be made available on the Company's website at www.allogene.com under the Investors tab in the News and Events section.
  • Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T) therapies for cancer.

BioNTech to Acquire Kite’s Neoantigen TCR Cell Therapy R&D Platform and Manufacturing Facility in Gaithersburg, MD

Retrieved on: 
Monday, July 19, 2021
Branches of biology, Medical specialties, Medicine, BioNTech, Immune system, Immunology, Cancer immunotherapy, T cells, Chimeric antigen receptor T cell, Pfizer–BioNTech COVID-19 vaccine

To support its growing cell therapy pipeline, BioNTech plans to further invest in the site including hiring additional personnel.

Key Points: 
  • To support its growing cell therapy pipeline, BioNTech plans to further invest in the site including hiring additional personnel.
  • Under the terms of the agreement, Kite will receive a one-time upfront payment from BioNTech to purchase Kites indiviualized solid tumor neoantigen TCR discovery platform as well as the Gaithersburg R&D and clinical manufacturing facility.
  • Kites new manufacturing facility in Frederick, MD for commercial production of CAR T-cell therapy is not part of the purchase agreement.
  • Kites neoantigen TCR platform enables the development of individualized TCR therapies that are custom designed to target individual neoantigens on a patients tumor.

GigaGen Publishes Research Describing Novel Mechanism of Action and Therapeutic Potential of its anti-CTLA-4 Drug Candidate, GIGA-564

Retrieved on: 
Wednesday, July 14, 2021
Clinical medicine, Medicine, Branches of biology, T cells, Immune system, Clusters of differentiation, Cancer immunotherapy, Antineoplastic drugs, Checkpoint inhibitor, Regulatory T cell, CTLA-4, Chemotherapy

The publication describes the novel mechanism of action of its anti-CTLA-4 drug candidate, GIGA-564, selected due to its reduced checkpoint inhibition, which resulted in superior anti-tumor activity and lower toxicity in murine models compared to commercially available anti-CTLA-4 drugs.

Key Points: 
  • The publication describes the novel mechanism of action of its anti-CTLA-4 drug candidate, GIGA-564, selected due to its reduced checkpoint inhibition, which resulted in superior anti-tumor activity and lower toxicity in murine models compared to commercially available anti-CTLA-4 drugs.
  • We selected GIGA-564 due to its minimal checkpoint inhibition and its ability to deplete intratumoral Tregs in the tumor.
  • GigaGen is advancing transformative antibody drugs for immune deficiency, infectious diseases and checkpoint resistant cancers by leveraging industry-leading, single-cell technologies.
  • In addition, GigaGens lead oncology asset, GIGA-564, is an anti-CTLA-4 monoclonal antibody that has demonstrated improved anti-tumor efficacy in vivo through a unique mechanism of action.

Coya Therapeutics to Participate at the LifeSci Partners Summer Symposium

Retrieved on: 
Wednesday, July 14, 2021
Branches of biology, Biology, Immune system, T cells, Immunology, Regulatory T cell, Coya, Exosome complex

HOUSTON, July 14, 2021 (GLOBE NEWSWIRE) -- Coya Therapeutics, Inc. (Coya), a clinical-stage biotechnology company developing first-in-class approaches utilizing autologous regulatory T cells (Treg) and Treg-derived exosome therapeutics for neurodegenerative and autoimmune diseases, today announced that Howard Berman, Ph.D., Chief Executive Officer of Coya Therapeutics, will provide a corporate update at the LifeSci Partners Summer Symposium on Wednesday, July 21, 2021, at 10:30 a.m.

Key Points: 
  • HOUSTON, July 14, 2021 (GLOBE NEWSWIRE) -- Coya Therapeutics, Inc. (Coya), a clinical-stage biotechnology company developing first-in-class approaches utilizing autologous regulatory T cells (Treg) and Treg-derived exosome therapeutics for neurodegenerative and autoimmune diseases, today announced that Howard Berman, Ph.D., Chief Executive Officer of Coya Therapeutics, will provide a corporate update at the LifeSci Partners Summer Symposium on Wednesday, July 21, 2021, at 10:30 a.m.
  • To register in advance for the presentation, please click here .
  • The presentation and archived webcast will also be accessible under Events in the news section of Coya website .
  • Headquartered in Houston, TX, Coya Therapeutics (TM) is a clinical-stage biotechnology company developing first-in-class and best-in-class approaches utilizing adoptive regulatory T cells (Tregs) to target disease.

Tevogen Bio Announces FDA Clearance of Investigational New Drug (IND) Application For its Cytotoxic T Cell Therapy for COVID-19

Retrieved on: 
Monday, July 12, 2021
Research, Infectious diseases, FDA, Genetics, Other Health, Biotechnology, Pharmaceutical, Health, Science, Other Science, Medical specialties, Immunology, Clinical medicine, Medicine, T cells, Immune system, CD8, TVGN-489, the Clinical Trial, Tevogen Bio, TVGN-489, THE CLINICAL TRIAL, TEVOGEN BIO

Tevogen Bio, a clinical stage biotechnology company, announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for TVGN-489, Allogeneic COVID-19 Specific Cytotoxic T Lymphocytes (CTLs), allowing Tevogen Bio to initiate clinical trial of its investigational COVID-19 treatment.

Key Points: 
  • Tevogen Bio, a clinical stage biotechnology company, announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for TVGN-489, Allogeneic COVID-19 Specific Cytotoxic T Lymphocytes (CTLs), allowing Tevogen Bio to initiate clinical trial of its investigational COVID-19 treatment.
  • The outcome of the patients receiving TVGN-489 will be compared to matched patients treated with the current standard of care.
  • Our novel platform allows the possibility of bringing personalized cell therapies to large patient populations, addressing one of the major limitations in these types of therapies.
  • TVGN-489 is highly purified SARS-CoV-2 specific cytotoxic CD8+ T lymphocytes programmed to detect targets from the entire viral genome.

Allogene Therapeutics Announces Participation in Two Upcoming Virtual Investor Conferences

Retrieved on: 
Monday, July 12, 2021
Clinical medicine, Medicine, Health sciences, Cancer immunotherapy, T cells, Breakthrough therapy, Gene therapy, Chimeric antigen receptor T cell, Lymphoma, ALLO-715, Kite Pharma

SOUTH SAN FRANCISCO, Calif., July 12, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) therapies for cancer, today announced that management plans to participate in two upcoming virtual investor conferences.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., July 12, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) therapies for cancer, today announced that management plans to participate in two upcoming virtual investor conferences.
  • Following the live audio webcast, a replay will be available on the Company's website for approximately 30 days.
  • Allogene Therapeutics, with headquarters inSouth San Francisco, is a clinical-stagebiotechnology company pioneering the development of allogeneic chimeric antigen receptor Tcell (AlloCAR T) therapies for cancer.
  • AlloCAR T is a trademark of Allogene Therapeutics, Inc.